132 related articles for article (PubMed ID: 1675036)
1. Usefulness of esmolol in unstable angina pectoris. European Esmolol Study Group.
Hohnloser SH; Meinertz T; Klingenheben T; Sydow B; Just H
Am J Cardiol; 1991 Jun; 67(16):1319-23. PubMed ID: 1675036
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of esmolol for unstable angina pectoris.
Wallis DE; Pope C; Littman WJ; Scanlon PJ
Am J Cardiol; 1988 Nov; 62(16):1033-7. PubMed ID: 2903659
[TBL] [Abstract][Full Text] [Related]
3. Ultra short-acting intravenous beta-adrenergic blockade as add-on therapy in acute unstable angina.
Barth C; Ojile M; Pearson AC; Labovitz AJ
Am Heart J; 1991 Mar; 121(3 Pt 1):782-8. PubMed ID: 1672051
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience with esmolol, a short-acting beta-adrenergic blocker in cardiac arrhythmias and myocardial ischemia.
Sung RJ; Blanski L; Kirshenbaum J; MacCosbe P; Turlapaty P; Laddu AR
J Clin Pharmacol; 1986 Mar; 26(S1):A15-A26. PubMed ID: 2870082
[TBL] [Abstract][Full Text] [Related]
5. Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol.
Barbier GH; Shettigar UR; Appunn DO
Int J Clin Pharmacol Ther; 1995 Apr; 33(4):212-8. PubMed ID: 7620691
[TBL] [Abstract][Full Text] [Related]
6. Esmolol in acute ischemic syndromes.
Mitchell RG; Stoddard MF; Ben-Yehuda O; Aggarwal KB; Allenby KS; Trillo RA; Loyd R; Chang CT; Labovitz AJ
Am Heart J; 2002 Nov; 144(5):E9. PubMed ID: 12422138
[TBL] [Abstract][Full Text] [Related]
7. Use of an ultrashort-acting beta-receptor blocker (esmolol) in patients with acute myocardial ischemia and relative contraindications to beta-blockade therapy.
Kirshenbaum JM; Kloner RF; McGowan N; Antman EM
J Am Coll Cardiol; 1988 Sep; 12(3):773-80. PubMed ID: 2900259
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of carvedilol in unstable angina pectoris.
Brunner M; Faber TS; Greve B; Keck A; Schnabel P; Jeron A; Meinertz T; Just H; Zehender M
Am J Cardiol; 2000 May; 85(10):1173-8. PubMed ID: 10801996
[TBL] [Abstract][Full Text] [Related]
9. Acute hemodynamic effects of beta-blockers in patients with severe congestive heart failure: comparison of celiprolol and esmolol.
Felix SB; Stangl V; Kieback A; Doerffel W; Staudt A; Wernecke KD; Baumann G; Stangl K
J Cardiovasc Pharmacol; 2001 Nov; 38(5):666-71. PubMed ID: 11602813
[TBL] [Abstract][Full Text] [Related]
10. Esmolol: a titratable short-acting intravenous beta blocker for acute critical care settings.
Turlapaty P; Laddu A; Murthy VS; Singh B; Lee R
Am Heart J; 1987 Oct; 114(4 Pt 1):866-85. PubMed ID: 2889341
[TBL] [Abstract][Full Text] [Related]
11. Use of an ultra short-acting beta-blocker in patients with acute myocardial ischemia.
Kirshenbaum JM; Kloner RA; Antman EM; Braunwald E
Circulation; 1985 Oct; 72(4):873-80. PubMed ID: 2863013
[TBL] [Abstract][Full Text] [Related]
12. Acute effects of nicardipine and esmolol on the cardiac cycle, intracardiac hemodynamic and endothelial shear stress in patients with unstable angina pectoris and moderate coronary stenosis: results from single center, randomized study.
Chen SL; Hu ZY; Zhang JJ; Ye F; Kan J; Xu T; Liu ZZ; Zhang YJ; Zhang JX; Chen M
Cardiovasc Ther; 2012 Jun; 30(3):162-71. PubMed ID: 22099625
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics and therapeutic efficacy of esmolol.
Wiest DB; Haney JS
Clin Pharmacokinet; 2012 Jun; 51(6):347-56. PubMed ID: 22515557
[TBL] [Abstract][Full Text] [Related]
14. Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy.
Mooss AN; Hilleman DE; Mohiuddin SM; Hunter CB
Ann Pharmacother; 1994 Jun; 28(6):701-3. PubMed ID: 7919552
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics and pharmacokinetics of esmolol, a short-acting beta-blocking agent, in children.
Cuneo BF; Zales VR; Blahunka PC; Benson DW
Pediatr Cardiol; 1994; 15(6):296-301. PubMed ID: 7838803
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. The Esmolol vs Placebo Multicenter Study Group.
Anderson S; Blanski L; Byrd RC; Das G; Engler R; Laddu A; Lee R; Rajfer S; Schroeder J; Steck JD
Am Heart J; 1986 Jan; 111(1):42-8. PubMed ID: 2868645
[TBL] [Abstract][Full Text] [Related]
17. The effect of heart rate control on myocardial ischemia among high-risk patients after vascular surgery.
Raby KE; Brull SJ; Timimi F; Akhtar S; Rosenbaum S; Naimi C; Whittemore AD
Anesth Analg; 1999 Mar; 88(3):477-82. PubMed ID: 10071990
[TBL] [Abstract][Full Text] [Related]
18. The safety and effectiveness of esmolol in the perioperative period in patients undergoing abdominal aortic surgery.
Harwood TN; Butterworth J; Prielipp RC; Royster RL; Hansen K; Plonk G; Dean R
J Cardiothorac Vasc Anesth; 1999 Oct; 13(5):555-61. PubMed ID: 10527224
[TBL] [Abstract][Full Text] [Related]
19. Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics.
Wiest D
Clin Pharmacokinet; 1995 Mar; 28(3):190-202. PubMed ID: 7758250
[TBL] [Abstract][Full Text] [Related]
20. Esmolol in the treatment of supraventricular tachyarrhythmias.
Das G; Ferris J
Can J Cardiol; 1988 May; 4(4):177-80. PubMed ID: 2899451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
